AbbVie Forecast, price target & analysts
AbbVie Target price 2025 - Analyst rating & recommendation
AbbVie Classifications & Recommendation:
AbbVie Price Target
| Target Price | $213.83 |
| Price | $186.11 |
| Potential |
14.90%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target AbbVie 2026 .
The average AbbVie target price is $213.83.
This is
14.90%
register free of charge
$251.00
34.87%
register free of charge
$170.00
8.66%
register free of charge
|
|
| A rating was issued by 30 analysts: 18 Analysts recommend AbbVie to buy, 11 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the AbbVie stock has an average upside potential 2026 of
14.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 56.33 | 59.85 |
| 3.71% | 6.24% | |
| EBITDA Margin | 44.17% | 47.33% |
| 4.98% | 7.15% | |
| Net Margin | 7.52% | 19.66% |
| 15.22% | 161.33% |
23 Analysts have issued a sales forecast AbbVie 2025 . The average AbbVie sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an AbbVie EBITDA forecast 2025. The average AbbVie EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 AbbVie Analysts have issued a net profit forecast 2025. The average AbbVie net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.39 | 6.66 |
| 12.13% | 178.66% | |
| P/E | 27.94 | |
| EV/Sales | 6.57 |
11 Analysts have issued a AbbVie forecast for earnings per share. The average AbbVie EPS is
This results in the following potential growth metrics and future valuations:
Current AbbVie Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Apr 22 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 29 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Apr 22 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
